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RestrictionOld World monkey TRIM5α proteins are known to block the replication of human immunodeﬁciency virus
and other retroviruses in a species-speciﬁc fashion. In this report, we show that speciﬁc forms of simian
TRIM5α proteins can restrict herpes simplex virus (HSV) infection. To deﬁne the effect of TRIM5α on HSV
replication, we examined HSV infection in HeLa cell lines that stably express simian and human orthologs of
TRIM5α proteins. We demonstrated that several simian TRIM5α proteins can restrict HSV replication, with
the TRIM5α protein of rhesus macaques showing the strongest inhibition of HSV infection. We also found
that the level of the inhibition of virus replication was viral strain-speciﬁc. TRIM5α is likely to inhibit HSV at
the early stage of infection; however, at later times of infection, the levels of TRIM5α are signiﬁcantly
decreased. Thus, some TRIM5α proteins exhibit antiviral effects that extend beyond retroviral infections, but
HSV may be able to reduce this restriction by reducing TRIM5α levels during the later phases of virus
replication. Our results also argue that TRIM5α is only part of the reduced level of HSV replication in rhesus
macaques, which are known to be less susceptible to HSV infection than other primates.
© 2009 Elsevier Inc. All rights reserved.Introduction
Herpes simplex virus (HSV), a human nuclear DNA virus, is capable
of replicating in a variety of cell types of many species (Roizman et al.,
2007). This broad host range has several possible explanations. First,
the HSV virion has approximately 12 envelope surface glycoproteins
that can facilitate entry into a range of cell types (Roizman et al.,
2007). Second, HSV uses the broadly distributed heparan moiety of
cell surface glycosaminoglycans for attachment to cells and at least
three different receptors for entry (Spear, 2004). Third, HSV has
multiple mechanisms for overcoming intracellular blocks to replica-
tion. These include (1) degradation of the TRIM19/PML protein
(Chelbi-Alix and de The, 1999) and disruption of nuclear domain 10
(ND-10) nuclear bodies (Maul et al., 1993) to prevent their restriction
of HSV infection (Everett et al., 2006), (2) blocking host cell
chromatin-silencing mechanisms to allow active lytic gene transcrip-
tion (Cliffe and Knipe, 2008; Gu and Roizman, 2007; Knipe and Cliffe,
2008), and (3) blocking interferon induction (Lin et al., 2004; Melroe
et al., 2004). These and likely other mechanisms allow a broad host
range for HSV replication.
Nevertheless, HSV infection of certain animal species such as
rhesus macaques does not lead to disease (Juan-Sallés et al., 1997;. Knipe).
Sanoﬁ Pasteur, Cambridge, MA
ase, Emory University School of
ll rights reserved.London et al., 1974), but the reasons for the avirulence of HSV in
rhesus macaques are not known. Rhesus macaques are used as a host
for simian immunodeﬁciency virus (Desrosiers and Ringler, 1989),
and this is considered to be an excellent nonhuman primate model for
acquired immunodeﬁciency syndrome (AIDS). HSV-based vaccine
vectors expressing SIV proteins have been tested in rhesus macaques
(Kaur et al., 2007; Murphy et al., 2000). Because the rhesus-SIV model
often serves as a measure of AIDS vaccine vector efﬁcacy (Barouch,
2008), it is important to understand the interactions of the viral
vectors with rhesus cells.
Several host factors have been shown to regulate retroviral
infection (Wolf and Goff, 2008). The tripartite motif 5α (TRIM5α)
protein was identiﬁed as a major factor involved in restricting human
immunodeﬁciency virus type 1 (HIV-1) infection in Old World
monkey cells (Stremlau et al., 2004; Zheng et al., 2005). TRIM5α is
believed to restrict infection at an early, postentry stage, likely by
speciﬁcally recognizing the capsid and promoting its premature
disassembly (Owens et al., 2003, 2004; Stremlau et al., 2006). Studies
with TRIM5α orthologs cloned from different primates, including Old
and New World monkeys and hominoids, showed that TRIM5α
inhibits retroviral infection in a species-speciﬁc fashion (Song et al.,
2005b; Yap et al., 2004).
TRIM5α is a member of the tripartite motif (TRIM) family of
proteins which contain a RING domain, one or two B-box domains,
and coiled-coil (CC) domains (Reymond et al., 2001). Some TRIM
proteins including TRIM5α contain a C-terminal B30.2 or SPRY
domain. The TRIM5α primary transcript can be spliced into several
isoforms but only the largest product of splicing, TRIM5α, which
contains the B.30.2 domain (493 amino acids in humans), has the
Fig. 1. Replication of HSV-1 KOS strain (A) and HSV-2 186 syn+ strain (B) in HeLa and
rhesus macaque ﬁbroblast cell lines. HeLa or rhesus macaque ﬁbroblast cells were
infected with HSV-1 or HSV-2 at an MOI of 3 PFU/cell. Total virus was harvested at the
times indicated, and yields were determined by plaque assay on Vero cells.
244 N. Reszka et al. / Virology 398 (2010) 243–250ability tomediate retroviral restriction (Stremlau et al., 2004). To date,
about 69 members of the TRIM family have been identiﬁed in the
human genome and some of their homologs have been found in
primates and other species.
Members of the TRIM protein family are involved in various
cellular processes including cell proliferation, differentiation, devel-
opment, oncogenesis and apoptosis (Nisole et al., 2005; Reymond et
al., 2001). Depending on their function, localization and cellular
partner, TRIM proteins can act in the nucleus or in the cytoplasm and
affect different stages of viral life cycles. TRIM19/PML, a major
component of nuclear domain 10 (ND10) bodies (Everett, 2001;Maul,
1998), interferes with replication of several DNA and RNA viruses
including HSV-1 (Everett and Maul, 1994), Ebola (Björndal et al.,
2003), VSV (Bonilla et al., 2002; Djavani et al., 2001), and arenaviruses
(Asper et al., 2004) among others (Blondel et al., 2002; Borden et al.,
1998; Turelli et al., 2001). TRIM19/PML is reported to associate with
proteins exerting various functions including transcription, DNA
repair, mRNA stability and chromatin remodeling (Everett and
Chelbi-Alix, 2007). Similar to TRIM5α (Sakuma et al., 2007),
TRIM19/PML is induced by type I IFNs. Some evidence indicates
that TRIM19/PML is an antiviral molecule involved in innate
resistance to viral infection (Regad and Chelbi-Alix, 2001). The
deﬁnition of the precise role of TRIM19/PML is complicated because
of the number of proteins that interact with this protein and the fact
that IFN I up-regulates other proteins (for example, PKR, 2′5′OAS and
Mx protein) directly involved in inhibition of virus replication (Nisole
et al., 2005).
Based on the structural and functional similarities between
TRIM19/PML and other TRIM5 proteins, we asked if TRIM5α could
inﬂuence HSV replication. Our results show that TRIM5 proteins from
Old World monkeys (OWM) can restrict HSV infection, and this
inhibition is viral strain-speciﬁc.We therefore hypothesize that TRIM5
protein may exhibit antiviral effects that inhibit viruses outside of the
retrovirus family. These antiviral effects may be countered in some
cases, such as late times in cells infected with HSV, by downregulation
of TRIM5α levels during the late phase of infection.
Results
HSV-1 and HSV-2 replication is reduced in rhesus macaque ﬁbroblasts
Several reports have indicated that rhesus macaques are less
susceptible to HSV infection than other primates and are poor non-
human primate models of HSV-1 and 2 infection (Juan-Sallés et al.,
1997; Levine et al., 1980; London et al., 1974). However, little is
known about the basis for this low susceptibility. To test directly the
ability of HSV to grow in rhesus cells, we investigated the replication
of HSV-1 and 2 in rhesus monkey ﬁbroblasts and compared this with
the replication of those viruses in permissive HeLa cells. HeLa cells and
rhesus macaque ﬁbroblast cell lines were infected with HSV-1 and
HSV-2 at anMOI of 3 PFU/cell. Infected cells were harvested at various
times post-infection, and the yields of progeny viruses were
determined on Vero cells. We found that the HSV-1 and HSV-2 yields
obtained from rhesus monkey ﬁbroblasts were signiﬁcantly reduced
when compared to yields from HeLa cells (pb0.05) (Fig. 1). Both
reached maximal values by 40 hpi, and yields in rhesus monkey
ﬁbroblasts were about 100-fold lower than the yields from HeLa cells
(Fig. 1). The reduced replication of HSV in rhesus cells led us to
investigate whether the rhesus TRIM5α protein contributed to the
reduced pemissiveness.
Rhesus TRIM5α protein restricts HSV infection
To determine if rhesus TRIM5α, a factor known to restrict HIV
infection, contributed to the restriction of HSV-1 and 2 in rhesus cells,
we examined HSV infection of HeLa cells that constitutively expressthe rhesus monkey TRIM5α protein (H-R cells). H-R cells have been
used to investigate the restricting activity of TRIM5α on different
retroviruses, including HIV-1, SIVmac and SIVagm, and have demon-
strated virus-speciﬁc inhibitory activities (Song et al., 2005b). We
infected H-R cells and the control H-L cells (that contain the empty
pLPCX vector) with HSV-1 or HSV-2 at MOI's ranging from 1–30 PFU/
cell. At 24 hpi the cells were harvested, and yields of HSV were
determined by titration on Vero cells. In H-R cells infected at lowMOIs
(1 and 3), we observed signiﬁcant reductions in viral yield for both
HSV-1 and HSV-2 (HSV-1 KOSMOI=1: p=0.04; HSV-1 KOSMOI=3:
p=0.003; HSV-2 186 MOI=1: p=0.014) compared with the yields
obtained from the control H-L line (Fig. 2). HSV-1 KOS virus yields
following infection of H-R cells were reduced by as much as 2-fold
(Fig. 2A), and HSV-2 186 replicationwas reduced by as much as 5-fold
compared to infection of H-L cells (Fig. 2B). At MOI=30, the viral
yields from theH-R cellswere similar to theH-L cells. Therefore, rhesus
monkey TRIM5α can reduce HSV replication at low MOI's, but the
effect of rhesus TRIM5α protein was overcome at higher MOI's.
Effect of other primate TRIM5α molecules on HSV infection
Because the effects of TRIM5α protein on retrovirus infection
depend on the species origin of the TRIM5α protein (Song et al.,
2005b), we asked if the source of TRIM5α inﬂuenced the effects on
HSV infection. We therefore compared the effects of TRIM5α
molecules from African green monkey, squirrel monkey, rhesus
monkey and human. HSV-2 replication in H-H cells expressing
human TRIM5α was similar to that in H-L cells containing the empty
expression vector (Fig. 3). Viral replication in H-AGM cells expressing
African greenmonkey (AGM)TRIM5αwas reducedby3.6-fold relative
to the control H-L cells (Fig. 3). Similarly, viral replication in H-R cells
expressing rhesus TRIM5α was reduced by 4.5-fold (Fig. 3), as
observed above. In contrast, viral replication in H-Sq cells expressing
squirrel monkey TRIM5αwas reduced by only 35%. HSV-2 infection of
Fig. 2. Effect of rhesus monkey TRIM5α protein on HSV replication at different
multiplicities of infection. H-R cells that express rhesus monkey TRIM5α or the H-L
control cells were infected with HSV-1 KOS strain (panel A) or with HSV-2 186 syn+
strain (panel B) at an MOI of 1, 3, 10 or 30 PFU/cell. The infections were harvested at
24 hpi, and viral yields were measured by plaque assay on Vero cells.
Fig. 4. Effect of rhesus TRIM5α protein on HSV-1 and HSV-2 protein synthesis as
measured by Western blots. A: H-R and H-L cells infected with HSV-1 KOS strain at an
MOI of 3 PFU/cell or mock-infected. The cells were harvested at the times indicated, and
viral protein expression was analyzed by Western blotting using anti-ICP4, ICP27 and
ICP8 antibodies. B: H-R and H-L cell lines infected with HSV-2 186 syn+ strain or mock
infected. The cells were harvested at the times indicated, and viral protein expression
was analyzed by Western blotting using anti-ICP27 and ICP8 antibodies. β-actin served
as the loading control.
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AGM) resulted in signiﬁcantly lower virus yields (H-R: p=0.04;
H-AGM: p=0.04) of all the tested cell lines. Expression of squirrel
monkey (NWM) TRIM5α modestly inhibited HSV-2 replication, and
human TRIM5α only slightly suppressed HSV-2 replication; however,
the reductions in virus yields in these cells were not statistically
signiﬁcant (PN0.05). Therefore, of the TRIM5α molecules that we
examined, OWM TRIM5α molecules demonstrated the strongest
inhibitory activity on HSV replication.
Effects of rhesus TRIM5α protein on HSV-1 and HSV-2 protein synthesis
Because the restrictive activity of TRIM5α on retroviruses is
thought to occur at an early stage of infection (Stremlau et al., 2006;Fig. 3. HSV-2 yields obtained from cell lines that stably express different TRIM5α
variants. H-R (rhesus monkey), H-H (human), H-AGM (African green monkey), H-Sq
(squirrel monkey) and H-L (control empty vector) cells were infected with HSV-2 186
syn+ strain at anMOI of 3 PFU/cell and harvested after 24 h. Viral yields weremeasured
on Vero cells.Wu et al., 2006), we hypothesized that rhesus monkey TRIM5αmight
also exert its restrictive activity on HSV infection at an early stage. If
this were the case, HSV IE viral protein synthesis would be decreased
in rhesus monkey TRIMα-expressing cell lines. To test this hypo-
thesis, we infected H-L control cells and H-R cells expressing rhesus
monkey TRIM5α with HSV-1 and HSV-2 and assayed viral protein
synthesis by Western blot analysis. The HSV-1 immediate-early ICP4
protein was detectable at 4 hpi in both cell lines and peaked at 6 hpi,
at which time approximately 2-fold lower levels of ICP4 were
observed in the H-R cells (Fig. 4A). Expression of the IE ICP27 protein
was reduced by 3-fold in H-R cells compared to H-L cells as early as at
4 hpi. Expression of the early ICP8 protein in the H-R cell line was
reduced by 4-fold in H-R cells compared to H-L cells at 4 hpi.
Therefore, the reduction in HSV-1 replication in H-R cells was
apparent at the level of IE gene expression.
In HSV-2 infected cells, the reduction of viral protein synthesis in
H-R cells was greater compared to the reduction in HSV-1 gene
expression. ICP8 and ICP27 were reduced by 5–7-fold at 4–10 hpi in
H-R cells compared with H-L cells (Fig. 4B). Therefore, the reduction
in HSV-2 replication in H-R cells could be explained by a similar
reduction in IE and E gene expression.
Effects of rhesus TRIM5α on different HSV strains
Because replication of HSV-1 strain KOS and HSV-2 strain 186 syn+
was reduced by rhesus TRIM5α, we investigated whether the
restriction extended to other HSV strains, including clinical isolates.
First, we infected H-R cells and the control H-L cells with the low
passage HSV-2 clinical isolate SD90-3P or the low passage laboratory
stain HSV-2 G. H-R cells showed reduced yields of HSV-2 laboratory
Fig. 5. Effect of rhesus TRIM5α on replication of different HSV-2- and HSV-1 strains. (A)
Infection of H-R cells with HSV-2 strains: HSV 2-G strain, SD90/3P strain or the HSV-2
laboratory strain 186 syn+. H-R cells that stably express rhesus monkey TRIM5α or the
control H-L cells were infected with HSV-2 186 syn+, G, or SD90-3P strains at an MOI of
3. The infections were harvested at 24 hpi, and viral yields were measured by plaque
assay on Vero cells. (B) Infections with HSV-1 strains. H-R cells that express rhesus
monkey TRIM5α or the control H-L cells were infectedwith HSV-1 strains F and 17syn+
at an MOI of 3. The infections were harvested at 24 hpi, and the viral yields were
measured by plaque assay on Vero cells.
Fig. 6. Localization of ICP0 in infected cells. H-L control cells (panel 1) or cells that expressed
or infected with HSV-1 KOS strain (panels D, E, F, G, H and I) and stained for ICP0 at 4 and
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(Fig. 5A). HSV-2 strain 186 syn+ was reduced by 12-fold, HSV-2
strain G was reduced by 4-fold, and the SD90-3P clinical isolate was
reduced by 2.5-fold in rhesus TRIM5α cells. In the second set of
experiments we infected H-R cells and the control H-L cells with the
HSV-1 lowpassage laboratory strain F or the laboratory strain 17 syn+.
In H-R cells we observed a 3.6-fold reduction of HSV-1 strain F in
H-R cells compared to H-L control cells (Fig. 5B). In contrast,
replication of HSV-1 strain 17syn+ was not signiﬁcantly inhibited
(pN0.05) in rhesus-TRIM5α cells. Therefore, both HSV-1 and HSV-2
strains were inhibited by TRIM5α, and the inhibition of HSV
replication in TRIM5 expressing cells appeared to be more viral
strain-speciﬁc than species-speciﬁc.
Effect of TRIM5α on HSV ICP0 distribution
It was reported recently that a cytoplasmic PML retained the HSV
infected cell protein 0 (ICP0) in the cytoplasm and reduced HSV-1
replication (McNally et al., 2008). Therefore, it was conceivable that
TRIM5α acted in a similar fashion. To test this hypothesis, we
examined the distribution of ICP0 in HSV-1 KOS virus-infected H-L,
H-R, and H-H cells. In H-L and H-H cells, we detected nuclear ICP0 by
1 hpi (results not shown). By 4 hpi, nuclear ICP0 had accumulated in
H-L and H-H cells, and small numbers of cytoplasmic punctate
structures containing ICP0 were observed (Fig. 6). By 8 hpi, more
punctate ICP0 was observed in infected H-L and H-H cells (Fig. 6,
panels G and I). In infected H-R cells, we observed increased numbers
of cells with cytoplasmic ICP0 by 4 hpi (Fig. 6, panel E), and by 8 hpi,
there was decreased nuclear ICP0 and more cytoplasmic ICP0 (Fig. 6,
panel H). Therefore, rhesus TRIM5α appeared to increase the amountsrhesus (panel 2) or human (panel 3) TRIM5αwere mock-infected (panels A, B, and C)
8 hpi.
Fig. 7. Localization of TRIM5α and ICP0 in infected cells. Cells that expressed rhesus
monkey or human TRIM5α were infected with HSV-1 KOS strain and stained for
TRIM5α (green) and ICP0 (red) at 4 hpi.
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cells to detect ICP0 and TRIM5α, we observed that, in HSV-1-infected
H-R cells, ICP0 localized to punctate structures near punctate
TRIM5α-containing structures (Fig. 7, panels A and C). In contrast,
in HSV-infected H-H cells, there were few ICP0-containing structures
localized near the Trim5α cytoplasmic punctate structures (Fig. 7,
panels B and D). Similar changes in ICP0 distribution were observed
in H-R cells infected with another HSV-1 strain, HSV-1 strain 17. In
total, these results suggested that TRIM5α might sequester ICP0 in
the cytoplasm, preventing its nuclear functions, and thereby
inhibiting HSV replication.
Effect of TRIM5α on HSV-1 ICP0-mutant replication
The increased cytoplasmic ICP0 in H-R cells suggested that the
inhibitionmight be due to cytoplasmic retention of ICP0 at early times
of infection. If this were the case, the reduction would be dependent
on ICP0, as observed previously for cytoplasmic PML (McNally et al.,
2008). We therefore determined if an ICP0 mutant virus showed
decreased replication in H-R cells relative to H-L cells. To this end, we
infected H-L and H-R cells with the ICP0 null and rescued viruses and
measured the viral yields at 24 hpi. The ICP0 null mutant virus yields
were 1.9-fold lower in H-R cells as compared with H-L cells while the
rescued virus gave 2.4-fold lower yields in H-R cells as compared with
H-L cells (Table 1). Therefore, the lack of ICP0 did not signiﬁcantly
affect the restriction of HSV-1 by TRIM5α. In total, the level of TRIM5α
inhibition in HSV-infected cells appeared to be independent of the
presence of ICP0.Table 1
Viral yields from cells infected with HSV-1 KOS 7134 ICP0-null mutant virus or HSV-1
KOS 7134-R rescued virus.
Virus Yield on H-L and H-R
cell linesa
Relative yields on
H-L cells versus H-R cells
H-R H-L
HSV-1 KOS 7134 (ICP0-) 5.8×104 1.1×105 1.9
HSV-1 KOS 7134R (ICPO+) 6.8×106 1.6×107 2.4
a The H-R and H-L cell lines were infected with HSV-1 7134 ICP0 null mutant or the
7134R rescued virus at an MOI of 1 PFU per cell and harvested after 24h. Viral yields
were measured on Vero cells.Levels of TRIM5α decrease in HSV-infected cells
We observed in the immunoﬂuorescence studies described above
that TRIM5 levels appeared to decrease at later times postinfection. To
more fully understand the interactions between TRIM5α and HSV, we
performed Western blot analysis on lysates from mock- or HSV-
infected H-R and H-L cells to determine if HSV infection affected
TRIM5α levels. Both HSV-1 and HSV-2 infection resulted in decreased
levels of TRIM5α (Fig. 8). In HSV-2-infected cells, TRIM5α decreased
by 4 hpi and was undetectable by 24 hpi. In HSV-1-infected cells,
TRIM5α decreased more slowly but was also undetectable by 24 hpi.
The 80 kDa band was likely a cellular protein that cross reacts with
anti-HA tag antibodies but provides a loading control on the blot.
To determine if the loss of TRIM5α was related to the restriction
of HSV replication, we infected or mock-infected cells that express
different TRIM5α molecules (H-L, H-R, H-Sq, H-H, H-AGM) with
HSV-2 virus and harvested the infected cultures at 4, 6 or 16 hpi. In
all cell lines tested, loss of TRIM5α started at 6 hpi, which coincided
with ICP8 expression (Fig. 9) and the protein was undetectable by
16 hpi (data not shown). Therefore, for all TRIM5α variants tested,
we observed approximately the same kinetics of TRIM5α loss.
However, viral gene expression, as observed by ICP8 expression,
(Fig. 9) obtained from the infected cultures (Fig. 3) was different for
these cell lines. These results argued that the level of TRIM5α-
mediated restriction of HSV replication by the different TRIM5α
proteins was not determined primarily by TRIM5α protein levels in
the infected cells. The ability of HSV to promote loss of TRIM5α in
infected cells may, however, reduce the overall effect of all of the
TRIM5α molecules.
Discussion
HSV has long been known to be unable to cause serious disease in
rhesus macaques (London et al., 1974), but little is known about the
mechanism(s) of this avirulence. In this study we observed that at
least certain HSV-1 and HSV-2 strains grow relatively poorly in
immortalized rhesus monkey ﬁbroblast cells, providing a potential
explanation for the lack of disease in HSV-infected macaques. We
therefore explored the effect of TRIM5α proteins on HSV replication
following the demonstration that rhesus monkey TRIM5α can inhibit
HIV-1 replication. In our study we tested different TRIM5α orthologs
from Old World and New World monkeys and from humans for their
effect on HSV replication in HeLa cells. Among the TRIM5α proteins
that were tested, TRIM5α from rhesus macaques (OWM) exhibited
the strongest inhibitory effect on herpes virus infection, and TRIM5α
of AGM also shows a signiﬁcant inhibitory effect on HSV growth and
protein expression. In contrast, the squirrel monkey TRIM5α
exhibited only a modest effect on HSV replication, and human
TRIM5α had little to no effect. These results indicate that TRIM5α
from certain monkey species can signiﬁcantly diminish replication of
HSV. This is only a part of the mechanism of restriction for HSV in
rhesus monkey cells because the reduced viral replication in rhesus
monkey cells relative to that in human cells is much greater than the
degree of HSV inhibition observed for rhesus monkey TRIM5α
expressed in human cells.
Mechanism of inhibition
We observed that viral IE gene expression is reduced in cells
expressing rhesus monkey TRIM5α. Therefore, TRIM5α acts at a very
early stage in HSV infection. Because TRIM5α is located in the
cytoplasm, it could be affecting viral entry, nuclear targeting of the
nucleocapsid, uncoating at the nuclear pores, or translation of IE gene
mRNA in the cytoplasm. TRIM5α could also be affecting IE and later
gene transcription, but this would have to be indirect because we
found no evidence that TRIM5α is re-directed into the nucleus in HSV-
Fig. 8. Levels of TRIM5α in cells infected with HSV-1 or HSV-2. The H-R or H-L cells were infected with HSV-1 KOS strain (panel A) or HSV-2 186 syn+ strain (panel B) at an MOI of 3
PFU/cell or mock-infected. The infected cells were harvested at the times indicated, and Western blots were performed to detect TRIM5α.
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VP16 virion transactivator from reaching the nucleus or prevent HSV
ICP0 from entering the nucleus, as recently postulated for a
cytoplasmic PML isoform (McNally et al., 2008). McNally et al.
(2008) reported that cytoplasmic PML exerts its antiviral activity by
decreasing viral gene expression via the cytoplasmic sequestration of
ICP0. ICP0 is a multifunctional viral protein involved in several
processes including the disruption of PML bodies (Everett et al., 2006)
and modiﬁcation of viral chromatin (Cliffe and Knipe, 2008; Gu and
Roizman, 2007). ICP0 can shuttle between the cytoplasm and nucleus
at later times postinfection (Kalamvoki et al., 2008; Lopez et al., 2001).
Our immunoﬂuorescence studies showed that cytoplasmic ICP0 co-
localizes with rhesus-monkey TRIM5α suggesting that ICP0 may
interact with the TRIM5α molecule. Thus it was conceivable that
similar to cytoplasmic PML, TRIM5α may sequester ICP0 in the
cytoplasm, preventing it from reaching the nucleus. However,
replication of an ICP0-null mutant virus was reduced by TRIM5α to
nearly the same extent as an ICP0+ virus; therefore, themechanism of
TRIM5α inhibition of HSV replication does not appear to require ICP0.
HIV-1 is inhibited by Old World monkey TRIM5αmolecules (Song
et al., 2005b; Yap et al., 2004), and this effect is believed to be due to
altered uncoating of the HIV genome, by either accelerating uncoating
(Stremlau et al., 2006) or causing degradation of the capsid (Wu et al.,
2006). If HSV uncoating is altered, it will be interesting to determine if
the HSV major capsid protein has ﬂexible loops similar to the HIV
capsid cyclophilin-binding loop that can bind TRIM5α. This would beFig. 9. Levels of different TRIM5α proteins in cells infected with HSV-2 186 syn+ strain. The H
MOI of 3 PFU/cell or mock-infected. The infected cells were harvested at 4 or 6 hpi. The resu
ICP8 and HA antibodies. β-actin served as the loading control.a candidate site for interaction between TRIM5α and the HSV
infection process.
We observed that TRIM5α protein is lost during HSV infection, and
HSV may have evolved to do this to limit the restrictive ability of
TRIM5α. Because all forms of TRIM5α were reduced in HSV-infected
cells regardless of their level of restrictive activity, the level of
reduction seems to not be the primary determinant of activity. In
addition, ICP0 was not required for the loss of TRIM5α from infected
cells (not shown); thus, the reduction in levels of TRIM5α appears to
occur by a different mechanism from the mechanism of PML degra-
dation promoted by ICP0.
TRIM5α and PML
The PML protein may contribute to an antiviral mechanism that
restricts HSV replication because depletion of PML increases viral gene
expression (Everett et al., 2006), although overexpression of PML does
not affect HSV replication (Lopez et al., 2002). However, the
mechanism of this restriction due to PML has not been elucidated.
PML is a component of nuclear domain 10 structures, which have been
postulated to affect chromatin structure (Ishov et al., 1999). Based on
the current evidence that it is a cytoplasmic protein, TRIM5α seems
unlikely to affect nuclear processes directly, except that it may retain
nuclear molecules like ICP0 or VP16 in the cytoplasm, as discussed
above. Thus, the mechanisms of restriction of HSV by PML and
TRIM5α may be very different.-R, H-H, H-AGM, H-S and H-L cell lines were infected with HSV-2 186 syn+ strain at an
lting lysates were resolved by SDS-PAGE and a Western blot was performed with anti-
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Based on our results, rhesus monkey and other Old World monkey
TRIM5α proteins comprise a part of the explanation for the limited
replication of HSV observed in these cells. Replication of HIV-1 is also
restricted by Old World monkey TRIM5α proteins, and the major
changes in the B30.2 domain of Old World monkey TRIM5α proteins
occurredmillions of years before humans evolved (Song et al., 2005a).
This report documents that TRIM5α affects DNA virus replication in
addition to the previously well-documented role in affecting
retrovirus replication. Therefore, TRIM5α may be part of a broader
antiviral resistance mechanism that evolved very early to prevent
viruses from crossing from one host species to another.
Implications for HSV studies in rhesus macaques
These results also have implications for the use of HSV vaccines
and vaccine vectors in rhesus macaques. Infection of rhesus macaques
with simian immunodeﬁciency virus (SIV) is one of the best
nonhuman primate models for AIDS (Desrosiers and Ringler, 1989),
and AIDS vaccines are being tested experimentally in rhesus
macaques (Desrosiers, 2004; Feinberg and Moore, 2002; Morgan
et al., 2008). We have tested HSV vectors expressing SIV proteins as
AIDS vaccines in rhesus macaques and have found that they induce
cellular and humoral responses that reduce SIV challenge viral loads
and disease (Kaur et al., 2007; Murphy et al., 2000; Kaur et al., in
preparation). The results from this study show that HSV infects rhesus
monkey cells poorly and that part of the restriction in rhesus monkey
cells is due to the TRIM5α protein. Other studies in progress have
shown that HSV vectors show reduced protein expression in rhesus
monkey cells (J. Sen and D.M. Knipe, manuscript in preparation).
These results in total suggest that tests of HSV vectors in rhesus
macaques may underestimate their immunogenicity in humans.
Materials and methods
Cells and viruses
Vero (ATCC) and U2OS (ATCC) cells were grown as described
(Taylor et al., 2003). HeLa-derived cell lines that stably express
TRIM5α variants (Song et al., 2005b; Stremlau et al., 2004) were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM) (Gibco-
BRL) with 5% heat-inactivated fetal calf serum (FCS), 5% heat-
inactivated bovine calf serum (BCS), streptomycin (100 μg/ml) and
penicillin (100 μg/ml) and supplemented with 1 μg/ml puromycin
(Sigma). The HeLa-LPCX (H-L) cell lines contain the empty pLPCX
vector; HeLa-R (H-R) cells express rhesus monkey TRIM5α; HeLa-H
(H-H) cells express human TRIM5α; HeLa-Sq (H-Sq) cells express
squirrel monkey TRIM5α; and HeLa-AGM (H-AGM) cells express
African green monkey (Cercopithecus aethiops tantalus) TRIM5α. The
TRIM5α orthologs are fused to epitope tags derived from inﬂuenza
virus hemaglutinin (HA) for detection. With the exception of human
TRIM5α, all TRIM5α proteins possess the HA tag at the N-terminus. In
the human TRIM5α construct the HA tag is at the C-terminus.
The wild-type HSV-1 KOS strain and HSV-2 186 syn+, HVS-2 G
(Ejercito, Kieff, and Roizman, 1968) and HSV-2 SD90 3P (T. Dudek, E.
Torres-Lopez andD.M. Knipe,manuscript in preparation) strainswere
propagated on Vero cells. The HSV-1 7134 (ICP0-) and 7134 R
(rescued) viruses (Cai et al., 1993) were propagated and titrated on
U2OS cells. Vero cellswere also used for plaque assays tomeasure virus
yields obtained from HeLa cells that stably express TRIM5α variants.
Antibodies
Rabbit polyclonal anti-HA tag antibody (ab13834), mouse mono-
clonal: anti-ICP4 HSV-1 (ab6514), anti-ICP27 HSV-1+HSV-2(ab31631), and anti-β actin (ab 8226) antibodies were purchased
from Abcam, Inc. Mouse monoclonal anti-ICP27 antibody was
purchased from Virusys Corporation. Mouse monoclonal anti-ICP5
and mouse monoclonal anti-ICP0 HSV-1 antibodies were purchased
from East Coast Bio, Inc. The 3-83 rabbit anti-ICP8 serum has been
described (Knipe et al., 1987). Secondary antibodies conjugated to
horseradish peroxidase were obtained from Santa Cruz Biotechnology
Inc. Secondary antibodies conjugated to Alexa 594 and Alexa 488 dyes
were obtained from Molecular Probes Inc.
Virus infection and viral yield assay
Cells were plated into culture dishes 24 h prior to virus infection to
obtain 100% conﬂuence at the time of infection. Cells were infected
with the viruses in cold phosphate-buffered sodium (PBS) containing
0.1% glucose and 1% heat-inactivated bovine calf serum (BCS). After
1 h adsorption at 37 °C, the cells were washed as follows: once with
PBS, once with low pH solution (40 mM citric acid, 10 mM KCl,
135 mM NaCl pH 3.0) to inactivate extracellular virus, twice with PBS,
once with DMEM containing 1% heat-inactivated fetal calf serum
(FCS) and then the cells were maintained in the same medium for
24 h. At the time of harvesting, an equal volume of sterile milk was
added to the infections. Cells were lysed by freeze–thawing and
sonication (30 s), and the lysate was clariﬁed by centrifugation
(Taylor and Knipe, 2003). The cell lysate was stored at −80 °C until
titration by plaque assay on Vero or U20S cells.
Analysis of protein expression by western blotting
Cultures were infected at a multiplicity of infection (MOI) of 3
plaque forming units (PFU)/ml. Cells infected with HSV-1 KOS were
harvested at 4, 6 or 8 hpi. Cells infected with HSV-2 186 syn+ were
harvested at 4, 6 or 10 hpi. Cell lysates were prepared by lysis in SDS-
PAGE sample buffer with Complete™ protease inhibitors (Roche).
Equal amounts of cell lysate from each infection were analyzed by
SDS-PAGE, and subsequent Western blot was performed as described
previously (Gao and Knipe, 1989; Simpson-Holley et al., 2004).
Statistical analysis
Statistical analysis was performed using two-sided Student's t-tests.
Immunoﬂuorescence
H-L, H-R and H-H cells were seeded for immunoﬂuorescence at
1.9×105 cells per well on glass coverslips in 24-well plates. Twenty-
four hours later, cellswere infectedwithHSV-1 KOS strain at anMOI of
3. At 4 and 8 hpi the cells were ﬁxed and stained with antibodies
speciﬁc for theHA tag or ICP0 as describedpreviously (Simpson-Holley
et al., 2004).
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